Specialized clinical stage Alzamend Neuro is a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder and PTSD, presenting an opportunity to engage with researchers and clinicians overseeing early-phase trials and potential combination therapies.

Innovative lithium platform AL001 employs a patented ionic cocrystal technology delivering lithium with proline and salicylate, offering a unique mechanism that may attract partnerships or licensing discussions with neuroscience drug developers and imaging centers interested in lithium-based brain delivery.

Imaging and AI collaboration Recent partnerships and presentations around lithium imaging and AI-powered imaging through QMENTA and ISMRM indicate a strong path for contract imaging services, data analytics collaborations, and site capabilities at leading hospitals such as Massachusetts General Hospital.

Clinical and academic ties Active collaboration with Massachusetts General Hospital for the AL001 Phase II study and engagements with medical and military research communities (Military Health System Symposium) create avenues for sponsored studies, investigator-initiated trials, and strategic research collaborations.

Funding and traction With modest revenue and around 30 million in funding, Alzamend is positioned for early commercial discussions, licensing talks, and CRO partnerships to advance phase milestones, positioning potential buyers or co-development partners in a favorable negotiating window.